Skip to main content

Table 2 Univariate and Multivariate Cox proportional hazards models to predict survival in patients with unresectable pancreatic cancer

From: Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab–paclitaxel or FOLFIRINOX: A post–hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study)

Variables Univariate analysis Multivariate analysis
  HR 95%CI P–value HR 95%CI P–value
Age       
<60 reference      
60–70 0.99 0.74 – 1.35 0.998 1.07 0.77 – 1.50 0.674
>70 0.99 0.70 – 1.39 0.936 1.08 0.73 – 1.59 0.710
Sex       
F reference      
M 0.92 0.71 – 1.19 0.517 0.96 0.71 – 1.28 0.766
ECOG PS       
0 reference      
1 1.54 1.16 – 2.04 0.003 1.43 1.03 – 1.93 0.033
2 or more 2.22 1.30 – 3.79 0.003 2.52 1.34 – 4.71 0.004
Body mass index       
<22 reference      
≥22 1.01 0.77 – 1.30 0.969 0.98 0.73 – 1.31 0.880
Tumor resection       
no reference      
yes 0.73 0.50 – 1.07 0.103 0.71 0.45 – 1.12 0.142
Pancreatic tumor location      
Head reference      
Body 1.04 0.78 – 1.39 0.800 0.89 0.63 – 1.25 0.496
Tail 1.14 0.81 – 1.61 0.461 0.72 0.47 – 1.10 0.133
Tumor size       
<20 reference      
20 – 40 0.99 0.67 – 1.47 0.979 0.94 0.60 – 1.47 0.775
>40 1.39 0.91 – 2.11 0.125 0.88 0.54 – 1.43 0.605
Histology       
Adenocarcinoma reference      
Others 1.09 0.75 – 1.56 0.656 1.26 0.83 – 1.90 0.280
Liver metastasis       
No reference      
Yes 2.08 1.61 – 2.69 < 0.001 1.85 1.26 – 2.73 0.002
Peritoneal metastasis       
No reference      
Yes 0.95 0.68 – 1.31 0.742 0.91 0.57 – 1.44 0.674
Lung metastasis       
No reference      
Yes 1.39 0.95 – 1.31 0.09 1.40 0.86 – 2.29 0.176
Number of metastasis       
0 or 1 reference      
2 or more 1.59 1.21 – 2.09 < 0.001 1.17 0.80 – 1.71 0.422
Ascites       
No reference      
Yes 1.52 1.12 – 2.05 0.007 1.37 0.93 – 2.00 0.112
Albumin (g/dL), n (%)       
>4 reference      
3 – 4 0.82 0.54 – 1.24 0.349 1.45 0.88 – 2.37 0.144
<3 0.56 0.36 – 0.88 0.012 1.29 0.72 – 2.27 0.399
LDH (U/L), n (%)       
<240 reference      
240 – 360 1.91 1.32 – 2.77 < 0.001 1.51 0.97 – 2.33 0.065
>360 2.90 1.36 – 6.19 0.006 2.88 1.35 – 6.82 0.007
CRP (mg/dL), n (%)       
<0.3 reference      
0.3–3.0 1.45 1.09 – 1.92 0.010 1.12 0.81 – 1.55 0.503
>3.0 3.04 2.09 – 4.43 < 0.001 2.04 1.23 – 3.36 0.005
CA19–9 (U/mL), n (%)       
<37 reference      
37 – 370 1.24 0.84 – 1.84 0.285 1.18 0.77 – 1.80 0.441
>370 1.91 1.36 – 2.68 < 0.001 1.45 1.01 – 2.07 0.043
AJCC TNM stage, n (%)      
III reference      
IV 1.73 1.24 – 2.44 0.001 1.14 0.70 – 1.86 0.606
First line regimen, n (%)       
FFX reference      
GnP 0.86 0.66 – 1.11 0.249 0.99 0.72 – 1.36 0.942
  1. Abbreviations: HR Hazard ratio, CI Confidence interval, ECOG PS Eastern Cooperative Oncology Group performance status, LDH lactate dehydrogenase, CRP C–reactive protein, CA19–9 carbohydrate antigen 19–9, AJCC American Joint Committee on Cancer, GnP gemcitabine plus nab–paclitaxel, FFX FOLFIRINOX